2.3 Study selection The initial search identified 1,356 articles
[3] In our H1 2026 research covering 95 pharmaceutical packaging decision makers across the United States and Canada, 68% reported that their organizations had already completed or initiated the transition to safety prefilled syringe formats for their primary branded injectable portfolios, with the majority citing institutional formulary requirements as the primary conversion catalyst
Zepbound (tirzepatide), a dual hormone agonist, amplifies weight loss by targeting two hormones
Due to the limitations of the included studies, further studies with large sample sizes are needed to draw more definite conclusions
Add the glucagon receptor and now youve got active energy burning on top
Flying with Wegovy Pack the Wegovy injection in your hand luggage, not the hold